Sage Therapeutics, Inc. (NASDAQ:SAGE) has analysts on the Bullish side this week.

October 2, 2018 - By Adrian Erickson

Sage Therapeutics, Inc. (NASDAQ:SAGE) LogoInvestors sentiment decreased to 1.71 in 2018 Q2. Its down 0.02, from 1.73 in 2018Q1. It dropped, as 24 investors sold Sage Therapeutics, Inc. shares while 58 reduced holdings. 49 funds opened positions while 91 raised stakes. 46.94 million shares or 3.88% more from 45.19 million shares in 2018Q1 were reported.
Macquarie Grp Inc Limited holds 13,500 shares. Northern Tru accumulated 224,686 shares or 0.01% of the stock. Captrust owns 4 shares for 0% of their portfolio. Blackrock Inc, New York-based fund reported 2.79M shares. Swiss Bancshares has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Tocqueville Asset Mgmt Limited Partnership has 97,295 shares for 0.19% of their portfolio. Balyasny Asset Management Limited Liability accumulated 14,231 shares or 0.01% of the stock. Driehaus Cap Mngmt Ltd Co stated it has 0.05% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Principal Gp has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). 6,197 are owned by Envestnet Asset Mngmt. Advsr Asset Mngmt owns 0% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 153,254 shares. Wellington Mngmt Group Inc Limited Liability Partnership has invested 0.07% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Tudor Inv Et Al holds 0.03% or 5,341 shares in its portfolio. Parallax Volatility Advisers Limited Partnership holds 0% or 3,665 shares. Moreover, Fiera Capital Corporation has 0.19% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 273,918 shares.

Since April 17, 2018, it had 0 buys, and 3 selling transactions for $15.06 million activity. FRATES JAMES M also sold $1.08 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares. $9.96M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by STARR KEVIN P on Tuesday, April 17.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 6 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SAGE Therapeutics had 6 analyst reports since April 23, 2018 according to SRatingsIntel. The stock has “Buy” rating by Chardan Capital Markets on Tuesday, May 22. The company was maintained on Wednesday, June 13 by Canaccord Genuity. The firm has “Overweight” rating by Morgan Stanley given on Friday, July 13. The rating was maintained by BMO Capital Markets with “Buy” on Monday, April 23. Below is a list of Sage Therapeutics, Inc. (NASDAQ:SAGE) latest ratings and price target changes.

06/08/2018 Broker: PiperJaffray Rating: Overweight New Target: $206 Initiates Coverage On
13/07/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $225 New Target: $228 Maintain
13/06/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $210 New Target: $220 Maintain
06/06/2018 Broker: Ladenburg Thalmann Rating: Buy New Target: $230 Initiates Coverage On
22/05/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $225.0000 Upgrade
23/04/2018 Broker: BMO Capital Markets Rating: Buy New Target: $203.0000 Maintain

The stock decreased 1.66% or $2.35 during the last trading session, reaching $138.9. About 274,731 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 95.81% since October 2, 2017 and is uptrending. It has outperformed by 80.19% the S&P500.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $6.48 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

Another recent and important Sage Therapeutics, Inc. (NASDAQ:SAGE) news was published by Businesswire.com which published an article titled: “Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)” on September 02, 2018.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>